Cite

    Bartoli, L. et al. (2020). Outcomes in patients with spinal muscular atrophy given nusinersen, onasemnogene abeparvovec or no treatment: an analysis based on restricted mean survival time. Expert opinion on orphan drugs. pp. 303-307. [Online].